

Direct inhibitor of AR/AR-V7 DNA binding for castration-resistant prostate cancer



ONCOLOGY	Candidate
Product Type	Small molecules
Indication	Castration-resistance prostate cancer (CRPC)
Target	Androgen receptor (AR) and AR-V7
MoA(Mechanism of Action)	Direct inhibition against DNA binding of Androgen receptor (AR) and AR-V7 : By directly inhibiting the DNA binding of AR and AR-V7, it inhibits the growth of prostate cancer cells regardless of androgen levels or the presence or absence of receptor domain.
Competitiveness	<ul style="list-style-type: none"> • EPI-7386 (ESSA Pharma, Phase 1 clinical trial): AR N-terminal domain inhibitor, currently in early-stage clinical development with limited efficacy. • ARV-110 (Arvinas, Phase 2 clinical trial): AR PROTAC (Proteolysis-Targeting Chimeras), an androgen antagonist conjugated protein degrader. Currently in mid-stage clinical development with limited efficacy.
Development Stage	Candidate
Route of Administration	PO